{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T10:49:02Z","timestamp":1780397342530,"version":"3.54.1"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,3,24]],"date-time":"2018-03-24T00:00:00Z","timestamp":1521849600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1007\/s11886-018-0975-x","type":"journal-article","created":{"date-parts":[[2018,3,24]],"date-time":"2018-03-24T08:48:13Z","timestamp":1521881293000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Addressing Multimorbidity and Polypharmacy in Individuals With Atrial Fibrillation"],"prefix":"10.1007","volume":"20","author":[{"given":"Fahad","family":"Shaikh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lachlan B.","family":"Pasch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip J.","family":"Newton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beata V.","family":"Bajorek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caleb","family":"Ferguson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,3,24]]},"reference":[{"issue":"1","key":"975_CR1","first-page":"482","volume":"73","author":"M Andrews","year":"2006","unstructured":"Andrews M, Nelson BP. Atrial fibrillation. Mt Sinai J Med. 2006;73(1):482\u201392.","journal-title":"Mt Sinai J Med"},{"issue":"9082","key":"975_CR2","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/S0140-6736(97)06359-9","volume":"350","author":"SM Narayan","year":"1997","unstructured":"Narayan SM, Cain ME, Smith JM. Atrial fibrillation. Lancet. 1997;350(9082):943\u201350. \n                      https:\/\/doi.org\/10.1016\/s0140-6736(97)06359-9\n                      \n                    .","journal-title":"Lancet"},{"issue":"9816","key":"975_CR3","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/S0140-6736(11)61514-6","volume":"379","author":"GYH Lip","year":"2012","unstructured":"Lip GYH, Tse HF, Lane DA. Atrial fibrillation. Lancet. 2012;379(9816):648\u201361. \n                      https:\/\/doi.org\/10.1016\/s0140-6736(11)61514-6\n                      \n                    .","journal-title":"Lancet"},{"issue":"6","key":"975_CR4","doi-asserted-by":"publisher","first-page":"425","DOI":"10.3109\/07853890.2011.554426","volume":"43","author":"S Miyazaki","year":"2011","unstructured":"Miyazaki S, Shah AJ, Scherr D, Ha\u00efssaguerre M. Atrial fibrillation: pathophysiology and current therapy. Ann Med. 2011;43(6):425\u201336. \n                      https:\/\/doi.org\/10.3109\/07853890.2011.554426\n                      \n                    .","journal-title":"Ann Med"},{"issue":"38","key":"975_CR5","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","volume":"37","author":"P Kirchhof","year":"2016","unstructured":"Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893\u2013962. \n                      https:\/\/doi.org\/10.1093\/eurheartj\/ehw210\n                      \n                    .","journal-title":"Eur Heart J"},{"issue":"21","key":"975_CR6","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jacc.2014.03.022","volume":"64","author":"CT January","year":"2014","unstructured":"January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, et al. 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association task force on practice guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64(21):e1\u201376. \n                      https:\/\/doi.org\/10.1016\/j.jacc.2014.03.022\n                      \n                    .","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"975_CR7","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.hfc.2009.12.004","volume":"6","author":"SA Lubitz","year":"2010","unstructured":"Lubitz SA, Yi BA, Ellinor PT. Genetics of atrial fibrillation. Heart Fail Clin. 2010;6(2):239\u201347. \n                      https:\/\/doi.org\/10.1016\/j.hfc.2009.12.004\n                      \n                    .","journal-title":"Heart Fail Clin"},{"issue":"3","key":"975_CR8","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1111\/j.1540-8159.1997.tb06117.x","volume":"20","author":"A Cappucci","year":"1997","unstructured":"Cappucci A. Risk of complications of atrial fibrillation. Pacing Clin Electrophysiol. 1997;20(3):2684\u201391.","journal-title":"Pacing Clin Electrophysiol"},{"issue":"21","key":"975_CR9","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1016\/j.jacc.2014.03.021","volume":"64","author":"CT January","year":"2014","unstructured":"January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC, et al. 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: executive summary. J Am Coll Cardiol. 2014;64(21):2246\u201380. \n                      https:\/\/doi.org\/10.1016\/j.jacc.2014.03.021\n                      \n                    .","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"975_CR10","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s40273-013-0028-7","volume":"31","author":"B Bruggenjurgen","year":"2013","unstructured":"Bruggenjurgen B, Kohler S, Ezzat N, Reinhold T, Willich SN. Cost effectiveness of antiarrhythmic medications in patients suffering from atrial fibrillation. PharmacoEconomics. 2013;31(3):195\u2013213. \n                      https:\/\/doi.org\/10.1007\/s40273-013-0028-7\n                      \n                    .","journal-title":"PharmacoEconomics"},{"issue":"2","key":"975_CR11","doi-asserted-by":"publisher","first-page":"706","DOI":"10.18549\/PharmPract.2016.02.706","volume":"14","author":"Y Wang","year":"2016","unstructured":"\u2022 Wang Y, Singh S, Bajorek B. Old age, high risk medication, polypharmacy: a \u201ctrilogy\u201d of risks in older patients with atrial fibrillation. Pharm Pract (Granada). 2016;14(2):706. \n                      https:\/\/doi.org\/10.18549\/PharmPract.2016.02.706\n                      \n                    . This study identified that polypharmacy can increase the risk of medication misadvernture in individuals with atrial fibrillation.","journal-title":"Pharm Pract (Granada)"},{"issue":"4","key":"975_CR12","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1370\/afm.983","volume":"7","author":"JM Valderas","year":"2009","unstructured":"Valderas JM, Starfield B, Sibbald B, Salisbury C, Roland M. Defining comorbidity: implications for understanding health and health services. Ann Fam Med. 2009;7(4):357\u201363. \n                      https:\/\/doi.org\/10.1370\/afm.983\n                      \n                    .","journal-title":"Ann Fam Med"},{"key":"975_CR13","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/0021-9681(70)90054-8","volume":"23","author":"AR Feinstein","year":"1970","unstructured":"Feinstein AR. The pre-therapeutic classification of co-morbidity in chronic disease. J Chronic Dis. 1970;23:455\u201368.","journal-title":"J Chronic Dis"},{"issue":"2","key":"975_CR14","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1177\/1753944712464101","volume":"7","author":"JC LaMori","year":"2013","unstructured":"LaMori JC, Mody SH, Gross HJ, daCosta DiBonaventura M, Patel AA, Schein JR, et al. Burden of comorbidities among patients with atrial fibrillation. Ther Adv Cardiovasc Dis. 2013;7(2):53\u201362. \n                      https:\/\/doi.org\/10.1177\/1753944712464101\n                      \n                    .","journal-title":"Ther Adv Cardiovasc Dis"},{"issue":"6","key":"975_CR15","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.ejim.2011.08.029","volume":"22","author":"A Nobili","year":"2011","unstructured":"Nobili A, Marengoni A, Tettamanti M, Salerno F, Pasina L, Franchi C, et al. Association between clusters of diseases and polypharmacy in hospitalized elderly patients: results from the REPOSI study. Eur J Intern Med. 2011;22(6):597\u2013602. \n                      https:\/\/doi.org\/10.1016\/j.ejim.2011.08.029\n                      \n                    .","journal-title":"Eur J Intern Med"},{"issue":"4","key":"975_CR16","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.115.018544","volume":"133","author":"JP Piccini","year":"2016","unstructured":"Piccini JP, Hellkamp AS, Washam JB, Becker RC, Breithardt G, Berkowitz SD, et al. Polypharmacy and the efficacy and safety of rivaroxaban versus warfarin in the prevention of stroke in patients with nonvalvular atrial fibrillation. Circulation. 2016;133(4):352\u201360. \n                      https:\/\/doi.org\/10.1161\/circulationaha.115.018544\n                      \n                    .","journal-title":"Circulation"},{"issue":"5","key":"975_CR17","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/s00392-015-0936-y","volume":"105","author":"M Proietti","year":"2016","unstructured":"Proietti M, Raparelli V, Olshansky B, Lip GYH. Polypharmacy and major adverse events in atrial fibrillation: observations from the AFFIRM trial. Clin Res Cardiol. 2016;105(5):412\u201320. \n                      https:\/\/doi.org\/10.1007\/s00392-015-0936-y\n                      \n                    .","journal-title":"Clin Res Cardiol"},{"issue":"1","key":"975_CR18","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s11606-014-2993-8","volume":"30","author":"W Leiss","year":"2015","unstructured":"Leiss W, Mean M, Limacher A, Righini M, Jaeger K, Beer HJ, et al. Polypharmacy is associated with an increased risk of bleeding in elderly patients with venous thromboembolism. J Gen Intern Med. 2015;30(1):17\u201324. \n                      https:\/\/doi.org\/10.1007\/s11606-014-2993-8\n                      \n                    .","journal-title":"J Gen Intern Med"},{"key":"975_CR19","doi-asserted-by":"publisher","first-page":"i2868","DOI":"10.1136\/bmj.i2868","volume":"353","author":"J Jaspers Focks","year":"2016","unstructured":"Jaspers Focks J, Brouwer MA, Wojdyla DM, Thomas L, Lopes RD, Washam JB, et al. Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial. BMJ. 2016;353:i2868. \n                      https:\/\/doi.org\/10.1136\/bmj.i2868\n                      \n                    .","journal-title":"BMJ"},{"issue":"4","key":"975_CR20","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1007\/s12325-013-0018-3","volume":"30","author":"A Hagendorff","year":"2013","unstructured":"Hagendorff A, Freytag S, Muller A, Klebs S. Pill burden in hypertensive patients treated with single-pill combination therapy\u2014an observational study. Adv Ther. 2013;30(4):406\u201319. \n                      https:\/\/doi.org\/10.1007\/s12325-013-0018-3\n                      \n                    .","journal-title":"Adv Ther"},{"key":"975_CR21","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1001\/archinte.165.10.1147","volume":"165","author":"RH Chapman","year":"2005","unstructured":"Chapman RH, Benner JS, Petrilla AA, Tierce JC, Collins SR, Battleman DS, et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med. 2005;165:1147\u201352.","journal-title":"Arch Intern Med"},{"issue":"11","key":"975_CR22","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJV, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981\u201392. \n                      https:\/\/doi.org\/10.1056\/NEJMoa1107039\n                      \n                    .","journal-title":"N Engl J Med"},{"issue":"12","key":"975_CR23","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139\u201351. \n                      https:\/\/doi.org\/10.1056\/NEJMoa0905561\n                      \n                    .","journal-title":"N Engl J Med"},{"issue":"22","key":"975_CR24","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","volume":"369","author":"RP Giugliano","year":"2013","unstructured":"Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093\u2013104. \n                      https:\/\/doi.org\/10.1056\/NEJMoa1310907\n                      \n                    .","journal-title":"N Engl J Med"},{"issue":"10","key":"975_CR25","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"MR Patel","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883\u201391. \n                      https:\/\/doi.org\/10.1056\/NEJMoa1009638\n                      \n                    .","journal-title":"N Engl J Med"},{"issue":"4","key":"975_CR26","doi-asserted-by":"publisher","first-page":"228","DOI":"10.14797\/mdcj-11-4-228","volume":"11","author":"AA Ogunsua","year":"2015","unstructured":"Ogunsua AA, Shaikh AY, Ahmed M, McManus DD. Atrial fibrillation and hypertension: mechanistic, epidemiologic, and treatment parallels. Methodist Debakey Cardiovasc J. 2015;11(4):228\u201334.","journal-title":"Methodist Debakey Cardiovasc J"},{"issue":"2","key":"975_CR27","doi-asserted-by":"publisher","first-page":"100","DOI":"10.2459\/JCM.0b013e3283640ff7","volume":"15","author":"LQ Zhao","year":"2014","unstructured":"Zhao LQ, Liu SW. Atrial fibrillation in essential hypertension: an issue of concern. J Cardiovasc Med (Hagerstown). 2014;15(2):100\u20136. \n                      https:\/\/doi.org\/10.2459\/JCM.0b013e3283640ff7\n                      \n                    .","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"975_CR28","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1007\/s11886-009-0062-4","volume":"11","author":"O Go","year":"2009","unstructured":"Go O, Rosendorff C. Hypertension and atrial fibrillation. Curr Cardiol Rep. 2009;11:430\u20135.","journal-title":"Curr Cardiol Rep"},{"issue":"10","key":"975_CR29","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/jhh.2011.105","volume":"26","author":"YF Lau","year":"2012","unstructured":"Lau YF, Yiu KH, Siu CW, Tse HF. Hypertension and atrial fibrillation: epidemiology, pathophysiology and therapeutic implications. J Hum Hypertens. 2012;26(10):563\u20139. \n                      https:\/\/doi.org\/10.1038\/jhh.2011.105\n                      \n                    .","journal-title":"J Hum Hypertens"},{"key":"975_CR30","unstructured":"Australia NHFo. Guideline for the diagnosis and management of hypertension in adults. National Heart Foundation of Australia. 2016."},{"issue":"7","key":"975_CR31","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1093\/oxfordjournals.eurheartj.a061500","volume":"4","author":"H Denolin","year":"1983","unstructured":"Denolin H, Kuhn H, Krayenbuehl H, Loogen F, Reale A. The defintion of heart failure. Eur Heart J. 1983;4(7):445\u20138. \n                      https:\/\/doi.org\/10.1093\/oxfordjournals.eurheartj.a061500\n                      \n                    .","journal-title":"Eur Heart J"},{"issue":"27","key":"975_CR32","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)developed with the special contribution of the heart failure association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129\u2013200. \n                      https:\/\/doi.org\/10.1093\/eurheartj\/ehw128\n                      \n                    .","journal-title":"Eur Heart J"},{"issue":"2","key":"975_CR33","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.hfc.2009.11.001","volume":"6","author":"SA Lubitz","year":"2010","unstructured":"Lubitz SA, Benjamin EJ, Ellinor PT. Atrial fibrillation in congestive heart failure. Heart Fail Clin. 2010;6(2):187\u2013200. \n                      https:\/\/doi.org\/10.1016\/j.hfc.2009.11.001\n                      \n                    .","journal-title":"Heart Fail Clin"},{"issue":"6","key":"975_CR34","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/S0002-9149(02)03373-8","volume":"91","author":"WH Maisel","year":"2003","unstructured":"Maisel WH, Stevenson LW. Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy. Am J Cardiol. 2003;91(6):2\u20138. \n                      https:\/\/doi.org\/10.1016\/s0002-9149(02)03373-8\n                      \n                    .","journal-title":"Am J Cardiol"},{"issue":"12 Suppl","key":"975_CR35","doi-asserted-by":"publisher","first-page":"S281","DOI":"10.1046\/j.1540-8167.2003.90404.x","volume":"14","author":"GV Naccarelli","year":"2003","unstructured":"Naccarelli GV, Hynes BJ, Wolbrette DL, Bhatta L, Khan M, Samii S, et al. Atrial fibrillation in heart failure: prognostic significance and management. J Cardiovasc Electrophysiol. 2003;14(12 Suppl):S281\u2013S6.","journal-title":"J Cardiovasc Electrophysiol"},{"issue":"46","key":"975_CR36","doi-asserted-by":"publisher","first-page":"3250","DOI":"10.1093\/eurheartj\/ehv513","volume":"36","author":"D Kotecha","year":"2015","unstructured":"Kotecha D, Piccini JP. Atrial fibrillation in heart failure: what should we do? Eur Heart J. 2015;36(46):3250\u20137. \n                      https:\/\/doi.org\/10.1093\/eurheartj\/ehv513\n                      \n                    .","journal-title":"Eur Heart J"},{"key":"975_CR37","unstructured":"National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand (Chronic Heart Failure Guidelines Expert Writing Panel). Guidelines for the prevention, detection and management of chronic heart failure in Australia. 2011."},{"issue":"12","key":"975_CR38","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1002\/clc.22209","volume":"36","author":"J Silva-Cardoso","year":"2013","unstructured":"Silva-Cardoso J, Zharinov OJ, Ponikowski P, Naditch-Br\u00fbl\u00e9 L, Lewalter T, Brette S, et al. Heart failure in patients with atrial fibrillation is associated with a high symptom and hospitalization burden: the RealiseAF survey. Clin Cardiol. 2013;36(12):766\u201374. \n                      https:\/\/doi.org\/10.1002\/clc.22209\n                      \n                    .","journal-title":"Clin Cardiol"},{"key":"975_CR39","first-page":"865","volume":"3","author":"W Wongcharoen","year":"2012","unstructured":"Wongcharoen W, S-A C. The pathophysiology of atrial fibrillation in heart failure. J Innov Cardiac Rhythm Manag. 2012;3:865\u20139.","journal-title":"J Innov Cardiac Rhythm Manag"},{"key":"975_CR40","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1136\/hrt.77.4.309","volume":"77","author":"MP Berg Van den","year":"1997","unstructured":"Van den Berg MP, Tuinenburg AE, Crijns HJ, Van Gelder IC, Gosselink AT, Lie KI. Heart failure and atrial fibrillation: current concepts and controversies. Heart. 1997;77:309\u201313.","journal-title":"Heart"},{"issue":"4","key":"975_CR41","doi-asserted-by":"publisher","first-page":"46","DOI":"10.5897\/JPAP2013.0001","volume":"4","author":"O Ozougwu","year":"2013","unstructured":"Ozougwu O. The pathogenesis and pathophysiology of type 1 and type 2 diabetes mellitus. J Physiol Pathophysiol. 2013;4(4):46\u201357. \n                      https:\/\/doi.org\/10.5897\/jpap2013.0001\n                      \n                    .","journal-title":"J Physiol Pathophysiol"},{"issue":"9","key":"975_CR42","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1161\/CIRCRESAHA.114.303211","volume":"114","author":"J Andrade","year":"2014","unstructured":"Andrade J, Khairy P, Dobrev D, Nattel S. The clinical profile and pathophysiology of atrial fibrillation: relationships among clinical features, epidemiology, and mechanisms. Circ Res. 2014;114(9):1453\u201368. \n                      https:\/\/doi.org\/10.1161\/CIRCRESAHA.114.303211\n                      \n                    .","journal-title":"Circ Res"},{"issue":"3","key":"975_CR43","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3109\/07853890.2016.1144930","volume":"48","author":"L Alves-Cabratosa","year":"2016","unstructured":"Alves-Cabratosa L, Garc\u00eda-Gil M, Comas-Cuf\u00ed M, Mart\u00ed R, Ponjoan A, Parramon D, et al. Diabetes and new-onset atrial fibrillation in a hypertensive population. Ann Med. 2016;48(3):119\u201327. \n                      https:\/\/doi.org\/10.3109\/07853890.2016.1144930\n                      \n                    .","journal-title":"Ann Med"},{"key":"975_CR44","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.ijcard.2015.03.052","volume":"184","author":"CA Goudis","year":"2015","unstructured":"Goudis CA, Korantzopoulos P, Ntalas IV, Kallergis EM, Liu T, Ketikoglou DG. Diabetes mellitus and atrial fibrillation: pathophysiological mechanisms and potential upstream therapies. Int J Cardiol. 2015;184:617\u201322. \n                      https:\/\/doi.org\/10.1016\/j.ijcard.2015.03.052\n                      \n                    .","journal-title":"Int J Cardiol"},{"issue":"5","key":"975_CR45","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1111\/jdi.12476","volume":"7","author":"G Sun","year":"2016","unstructured":"Sun G, Ma M, Ye N, Wang J, Chen Y, Dai D, et al. Diabetes mellitus is an independent risk factor for atrial fibrillation in a general Chinese population. J Diabetes Investig. 2016;7(5):791\u20136. \n                      https:\/\/doi.org\/10.1111\/jdi.12476\n                      \n                    .","journal-title":"J Diabetes Investig"},{"issue":"8","key":"975_CR46","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1007\/s11606-010-1340-y","volume":"25","author":"S Dublin","year":"2010","unstructured":"Dublin S, Glazer NL, Smith NL, Psaty BM, Lumley T, Wiggins KL, et al. Diabetes mellitus, glycemic control, and risk of atrial fibrillation. J Gen Intern Med. 2010;25(8):853\u20138. \n                      https:\/\/doi.org\/10.1007\/s11606-010-1340-y\n                      \n                    .","journal-title":"J Gen Intern Med"},{"issue":"8","key":"975_CR47","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1161\/STROKEAHA.115.009371","volume":"46","author":"TF Overvad","year":"2015","unstructured":"Overvad TF, Skjoth F, Lip GY, Lane DA, Albertsen IE, Rasmussen LH, et al. Duration of diabetes mellitus and risk of thromboembolism and bleeding in atrial fibrillation: nationwide cohort study. Stroke. 2015;46(8):2168\u201374. \n                      https:\/\/doi.org\/10.1161\/STROKEAHA.115.009371\n                      \n                    .","journal-title":"Stroke"},{"issue":"6","key":"975_CR48","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1177\/2047487315599892","volume":"23","author":"JL Pallisgaard","year":"2016","unstructured":"Pallisgaard JL, Schjerning AM, Lindhardt TB, Procida K, Hansen ML, Torp-Pedersen C, et al. Risk of atrial fibrillation in diabetes mellitus: a nationwide cohort study. Eur J Prev Cardiol. 2016;23(6):621\u20137. \n                      https:\/\/doi.org\/10.1177\/2047487315599892\n                      \n                    .","journal-title":"Eur J Prev Cardiol"},{"issue":"4","key":"975_CR49","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.acvd.2015.01.009","volume":"108","author":"M Tadic","year":"2015","unstructured":"Tadic M, Cuspidi C. Type 2 diabetes mellitus and atrial fibrillation: from mechanisms to clinical practice. Arch Cardiovasc Dis. 2015;108(4):269\u201376. \n                      https:\/\/doi.org\/10.1016\/j.acvd.2015.01.009\n                      \n                    .","journal-title":"Arch Cardiovasc Dis"},{"issue":"39","key":"975_CR50","doi-asserted-by":"publisher","first-page":"3035","DOI":"10.1093\/eurheartj\/eht108","volume":"34","author":"L Ryden","year":"2013","unstructured":"Authors\/Task Force M, Ryden L, Grant PJ, Anker SD, Berne C, Cosentino F, et al. ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the task force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of diabetes (EASD). Eur Heart J. 2013;34(39):3035\u201387. \n                      https:\/\/doi.org\/10.1093\/eurheartj\/eht108\n                      \n                    .","journal-title":"Eur Heart J"},{"key":"975_CR51","first-page":"884","volume":"51","author":"K Carroll","year":"2001","unstructured":"Carroll K, Majeed A. Comorbidity associated with atrial fibrillation: a general practice-based study. Br J Gen Pract. 2001;51:884\u201391.","journal-title":"Br J Gen Pract"},{"issue":"9","key":"975_CR52","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1161\/STROKEAHA.114.006070","volume":"45","author":"L Friberg","year":"2014","unstructured":"Friberg L, Rosenqvist M, Lindgren A, Terent A, Norrving B, Asplund K. High prevalence of atrial fibrillation among patients with ischemic stroke. Stroke. 2014;45(9):2599\u2013605. \n                      https:\/\/doi.org\/10.1161\/STROKEAHA.114.006070\n                      \n                    .","journal-title":"Stroke"},{"key":"975_CR53","doi-asserted-by":"publisher","first-page":"22628","DOI":"10.3402\/ijch.v72i0.22628","volume":"72","author":"K Bjorn-Mortensen","year":"2013","unstructured":"Bjorn-Mortensen K, Lynggaard F, Lynge PM. High prevalence of atrial fibrillation among Greenlanders with ischemic stroke\u2014atrial fibrillation found in more than 30% of cases. Int J Circumpolar Health. 2013;72:22628. \n                      https:\/\/doi.org\/10.3402\/ijch.v72i0.22628\n                      \n                    .","journal-title":"Int J Circumpolar Health"},{"issue":"5","key":"975_CR54","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1111\/ene.12671","volume":"22","author":"SF Jespersen","year":"2015","unstructured":"Jespersen SF, Christensen LM, Christensen A, Christensen H. Increasing rate of atrial fibrillation from 2003 to 2011 in patients with ischaemic stroke: results from 55,551 patients in a nationwide registry. Eur J Neurol. 2015;22(5):839\u201344. \n                      https:\/\/doi.org\/10.1111\/ene.12671\n                      \n                    .","journal-title":"Eur J Neurol"},{"issue":"8","key":"975_CR55","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1093\/eurheartj\/ehn599","volume":"31","author":"L Friberg","year":"2010","unstructured":"Friberg L, Hammar N, Rosenqvist M. Stroke in paroxysmal atrial fibrillation: report from the Stockholm cohort of atrial fibrillation. Eur Heart J. 2010;31(8):967\u201375. \n                      https:\/\/doi.org\/10.1093\/eurheartj\/ehn599\n                      \n                    .","journal-title":"Eur Heart J"},{"issue":"5","key":"975_CR56","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1080\/07853890701320662","volume":"39","author":"I Savelieva","year":"2007","unstructured":"Savelieva I, Bajpai A, Camm AJ. Stroke in atrial fibrillation: update on pathophysiology, new antithrombotic therapies, and evolution of procedures and devices. Ann Med. 2007;39(5):371\u201391. \n                      https:\/\/doi.org\/10.1080\/07853890701320662\n                      \n                    .","journal-title":"Ann Med"},{"key":"975_CR57","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1161\/CIRCULATIONAHA.115.016595","volume":"131","author":"RA Vermond","year":"2015","unstructured":"Vermond RA, Gelder ICV, Crijns HJ, Rienstra M. Does myocardial infarction beget atrial fibrillation and atrial fibrillation beget myocardial infarction? Circulation. 2015;131:1824\u20136.","journal-title":"Circulation"},{"issue":"1","key":"975_CR58","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1001\/jamainternmed.2013.11912","volume":"174","author":"EZ Soliman","year":"2014","unstructured":"Soliman EZ, Safford MM, Muntner P, Khodneva Y, Dawood FZ, Zakai NA, et al. Atrial fibrillation and the risk of myocardial infarction. JAMA Intern Med. 2014;174(1):107\u201314. \n                      https:\/\/doi.org\/10.1001\/jamainternmed.2013.11912\n                      \n                    .","journal-title":"JAMA Intern Med"},{"issue":"19","key":"975_CR59","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1161\/CIRCULATIONAHA.111.030171","volume":"123","author":"SA Lubitz","year":"2011","unstructured":"Lubitz SA, Magnani JW, Ellinor PT, Benjamin EJ. Atrial fibrillation and death after myocardial infarction: risk marker or causal mediator? Circulation. 2011;123(19):2063\u20135. \n                      https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.111.030171\n                      \n                    .","journal-title":"Circulation"},{"key":"975_CR60","doi-asserted-by":"publisher","unstructured":"Violi F, Soliman EZ, Pignatelli P, Pastori D. Atrial fibrillation and myocardial infarction: a systematic review and appraisal of pathophysiologic mechanisms. J Am Heart Assoc. 2016;5(5). \n                      https:\/\/doi.org\/10.1161\/JAHA.116.003347\n                      \n                    .","DOI":"10.1161\/JAHA.116.003347"},{"issue":"4","key":"975_CR61","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.ahj.2013.07.013","volume":"166","author":"AM Chamberlain","year":"2013","unstructured":"Chamberlain AM, Bielinski SJ, Weston SA, Klaskala W, Mills RM, Gersh BJ, et al. Atrial fibrillation in myocardial infarction patients: impact on health care utilization. Am Heart J. 2013;166(4):753\u20139. \n                      https:\/\/doi.org\/10.1016\/j.ahj.2013.07.013\n                      \n                    .","journal-title":"Am Heart J"},{"issue":"5","key":"975_CR62","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1177\/1715163513500208","volume":"146","author":"B Farrell","year":"2013","unstructured":"Farrell B, French Merkley V, Ingar N. Reducing pill burden and helping with medication awareness to improve adherence. Can Pharm J (Ott). 2013;146(5):262\u20139. \n                      https:\/\/doi.org\/10.1177\/1715163513500208\n                      \n                    .","journal-title":"Can Pharm J (Ott)"},{"issue":"5","key":"975_CR63","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s40266-013-0064-1","volume":"30","author":"J Tjia","year":"2013","unstructured":"Tjia J, Velten SJ, Parsons C, Valluri S, Briesacher BA. Studies to reduce unnecessary medication use in frail older adults: a systematic review. Drugs Aging. 2013;30(5):285\u2013307. \n                      https:\/\/doi.org\/10.1007\/s40266-013-0064-1\n                      \n                    .","journal-title":"Drugs Aging"},{"issue":"2","key":"975_CR64","doi-asserted-by":"publisher","first-page":"383","DOI":"10.2147\/CIA.S2468","volume":"3","author":"RL Bushardt","year":"2008","unstructured":"Bushardt RL, Massey EB, Simpson TW, Ariail JC, Simpson KN. Polypharmacy: misleading, but manageable. Clin Interv Aging. 2008;3(2):383\u20139.","journal-title":"Clin Interv Aging"},{"issue":"1","key":"975_CR65","doi-asserted-by":"publisher","first-page":"68","DOI":"10.4103\/0971-6580.94506","volume":"19","author":"S Rambhade","year":"2012","unstructured":"Rambhade S, Chakarborty A, Shrivastava A, Patil UK, Rambhade A. A survey on polypharmacy and use of inappropriate medications. Toxicol Int. 2012;19(1):68\u201373. \n                      https:\/\/doi.org\/10.4103\/0971-6580.94506\n                      \n                    .","journal-title":"Toxicol Int"},{"issue":"2","key":"975_CR66","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1177\/1474515116642604","volume":"16","author":"C Ferguson","year":"2017","unstructured":"\u2022\u2022 Ferguson C, Inglis SC, Newton PJ, Middleton S, Macdonald PS, Davidson PM. Multi-morbidity, frailty and self-care: important considerations in treatment with anticoagulation drugs. Outcomes of the AFASTER study. Eur J Cardiovasc Nurs. 2017;16(2):113\u201324. \n                      https:\/\/doi.org\/10.1177\/1474515116642604\n                      \n                    . This study highlighted that multi-morbidity, frailty and self-care as important considerations in anticoagulation decision-making.","journal-title":"Eur J Cardiovasc Nurs"},{"issue":"4","key":"975_CR67","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1111\/pace.12575","volume":"38","author":"Y-F Hu","year":"2015","unstructured":"Hu Y-F, Liao J-N, Chern C-M, Weng C-H, Lin Y-J, Chang S-L, et al. Identification and management of noncompliance in atrial fibrillation patients receiving dabigatran: the role of a drug monitor. Pacing Clin Electrophysiol: PACE. 2015;38(4):465\u201371. \n                      https:\/\/doi.org\/10.1111\/pace.12575\n                      \n                    .","journal-title":"Pacing Clin Electrophysiol: PACE"},{"key":"975_CR68","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Patterson SM, Cadogan CA, Kerse N, Cardwell CR, Bradley MC, Ryan C et al. Interventions to improve the appropriate use of polypharmacy for older people. Cochrane Database Syst Rev. 2014(10):CD008165. \n                      https:\/\/doi.org\/10.1002\/14651858.CD008165.pub3\n                      \n                    . This Cochrane review revealed that interventions such as pharmaceutical care appears to be beneficial to reduce inappropriate prescribing and medication related problems.","DOI":"10.1002\/14651858.CD008165.pub3"},{"issue":"133","key":"975_CR69","first-page":"1","volume":"10","author":"A Ahmad","year":"2010","unstructured":"Ahmad A, Hugtenburg J, Welschen LM, Dekker JM, Nijpels G. Effect of medication review and cognitive behaviour treatment by community pharmacists of patients discharged from the hospital on drug related problems and compliance: design of a randomized controlled trial. BioMedCentral Public Health. 2010;10(133):1\u201310.","journal-title":"BioMedCentral Public Health"},{"key":"975_CR70","first-page":"235","volume":"29","author":"M-S Wen","year":"2013","unstructured":"Wen M-S, Lee MTM. Warfarin pharmacogenetics: NewLife for an old drug. Acta Cardiologica Sinica. 2013;29:235\u201342.","journal-title":"Acta Cardiologica Sinica"},{"issue":"2","key":"975_CR71","doi-asserted-by":"publisher","first-page":"165","DOI":"10.3978\/j.issn.2072-1439.2015.01.23","volume":"7","author":"CM Hanley","year":"2015","unstructured":"Hanley CM, Kowey PR. Are the novel anticoagulants better than warfarin for patients with atrial fibrillation? J Thorac Dis. 2015;7(2):165\u201371. \n                      https:\/\/doi.org\/10.3978\/j.issn.2072-1439.2015.01.23\n                      \n                    .","journal-title":"J Thorac Dis"},{"issue":"9921","key":"975_CR72","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","volume":"383","author":"CT Ruff","year":"2014","unstructured":"Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955\u201362. \n                      https:\/\/doi.org\/10.1016\/s0140-6736(13)62343-0\n                      \n                    .","journal-title":"Lancet"},{"key":"975_CR73","doi-asserted-by":"publisher","first-page":"167","DOI":"10.2147\/PPA.S56187","volume":"8","author":"JC Choi","year":"2014","unstructured":"Choi JC, Dibonaventura MD, Kopenhafer L, Nelson WW. Survey of the use of warfarin and the newer anticoagulant dabigatran in patients with atrial fibrillation. Patient Prefer Adherence. 2014;8:167\u201377. \n                      https:\/\/doi.org\/10.2147\/PPA.S56187\n                      \n                    .","journal-title":"Patient Prefer Adherence"},{"key":"975_CR74","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2147\/VHRM.S39571","volume":"9","author":"C Ferguson","year":"2013","unstructured":"Ferguson C, Inglis SC, Newton PJ, Middleton S, Macdonald PS, Davidson PM. Atrial fibrillation and thromboprophylaxis in heart failure: the need for patient-centered approaches to address adherence. Vasc Health Risk Manag. 2013;9:3\u201311. \n                      https:\/\/doi.org\/10.2147\/VHRM.S39571\n                      \n                    .","journal-title":"Vasc Health Risk Manag"},{"issue":"1","key":"975_CR75","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3821\/1913-701X-143.1.37","volume":"143","author":"M Rosenthal","year":"2010","unstructured":"Rosenthal M, Austin Z, Tsuyuki RT. Are pharmacists the ultimate barrier to pharmacy practice change? Can Pharm J \/ Rev Pharm Can. 2010;143(1):37\u201342. \n                      https:\/\/doi.org\/10.3821\/1913-701X-143.1.37\n                      \n                    .","journal-title":"Can Pharm J \/ Rev Pharm Can"},{"issue":"2","key":"975_CR76","doi-asserted-by":"publisher","first-page":"102","DOI":"10.3821\/1913701X2008141102ASRORS20CO2","volume":"141","author":"P Chan","year":"2008","unstructured":"Chan P, Grindrod KA, Bougher D, Pasutto FM, Wilgosh C, Eberhart G, et al. A systematic review of remuneration systems for clinical pharmacy care services. Can Pharm J \/ Rev Pharm Can. 2008;141(2):102\u201312. \n                      https:\/\/doi.org\/10.3821\/1913701X2008141102ASRORS20CO2\n                      \n                    .","journal-title":"Can Pharm J \/ Rev Pharm Can"}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11886-018-0975-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-018-0975-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-018-0975-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,24]],"date-time":"2019-03-24T00:29:54Z","timestamp":1553387394000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11886-018-0975-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,24]]},"references-count":76,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["975"],"URL":"https:\/\/doi.org\/10.1007\/s11886-018-0975-x","relation":{},"ISSN":["1523-3782","1534-3170"],"issn-type":[{"value":"1523-3782","type":"print"},{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,24]]},"assertion":[{"value":"24 March 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Fahad Shaikh, Lachlan B. Pasch, Phillip J. Newton, Beata V. Bajorek, and Caleb Ferguson declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"32"}}